Рembrolizumab as second line therapy for hepatocellular patient by I. A. Dzhanyan, V. V. Breder, O. I. Borisova, K. K. Laktionov

Get full text

Five-year results of nivolumab for the treatment of non-small cell lung cancer in clinical practice of the N.N. Blokhin Russian Cancer Research Center by D. I. Yudin, K. K. Laktionov, K. A. Sarantseva, V. V. Breder, M. S. Ardzinba, E. V. Reutova, O. I. Borisova

Get full text

Pseudoprogression in patients on immunotherapy by D. I. Yudin, K. K. Laktionov, K. A. Sarantseva, V. V. Breder, E. V. Reutova, O. I. Borisova, M. S. Ardzinba

Get full text

Immuno-related endocrinopathy in patients treated with immune checkpoint inhibitors by D. I. Yudin, K. K. Laktionov, K. A. Sarantseva, O. I. Borisova, V. V. Breder, E. V. Reutova, M. F. Beloyartseva, S. Yu. Kruteleva, I. A. Dzhanyan

Get full text

COMPARATIVE ANALYSIS OF BIOLOGICAL EFFECTS OF SELECTIVE ACTIVATOR OF THE GLUCOCORTICOID RECEPTOR CPDA ON DIFFERENT SUBTYPES OF BREAST CANCER CELL LINES by E. M. Zhidkova, K. A. Kuzin, L. R. Tilova, A. V. Savinkova, O. I. Borisova, M. D. Lavrova, V. P. Maximova, K. I. Kirsanov, M. G. Yakubovskaya, E. A. Lesovaya

Get full text